OMEROS CORP Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- OMEROS CORP stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $2.86M, a 11332.00% increase year-over-year.
- OMEROS CORP stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $8.21M, a 12928.57% increase year-over-year.
- OMEROS CORP stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $225.00K, a 1223.53% increase year-over-year.
- OMEROS CORP stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $25.00K, a 733.33% increase year-over-year.
- OMEROS CORP stock issued during period, value, stock options exercised for fiscal 2025 was $7.65M, a 1298.72% increase from fiscal 2024.
- OMEROS CORP stock issued during period, value, stock options exercised for fiscal 2024 was $547.00K, a 264.67% increase from fiscal 2023.
- OMEROS CORP stock issued during period, value, stock options exercised for fiscal 2023 was $150.00K, a 63.86% decline from fiscal 2022.
- OMEROS CORP stock issued during period, value, stock options exercised for fiscal 2022 was $415.00K, a 95.05% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $2.86M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $8.21M 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $7.65M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $225.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $25.00K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $63.00K 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $547.00K 10-K · filed 2025-03-31 | |
| 2024-09-30 | $17.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $3.00K 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $32.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $150.00K 10-K · filed 2026-03-31 | |
| 2023-09-30 | $53.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $97.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $415.00K 10-K · filed 2025-03-31 | |
| 2022-03-31 | $414.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $8.38M 10-K · filed 2024-04-01 | |
| 2021-09-30 | $608.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.14M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $6.33M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $5.02M 10-K · filed 2023-03-13 | |
| 2020-09-30 | $2.20M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $66.00K 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $2.71M 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $7.60M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $3.33M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $1.60M 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $108.00K 10-Q · filed 2020-11-09 | |
| 2018-12-31 | $6.73M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $3.84M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $2.19M 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $687.00K 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $11.77M 10-K · filed 2020-03-02 | |
| 2016-12-31 | $3.15M 10-K · filed 2019-03-01 | |
| 2015-12-31 | $1.42M 10-K · filed 2018-03-01 | |
| 2014-12-31 | $1.80M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $662.00K 10-K · filed 2016-03-15 | |
| 2012-12-31 | $369.00K 10-K · filed 2015-03-16 | |
| 2011-12-31 | $595.00K 10-K · filed 2014-03-13 | |
| 2010-12-31 | $299.00K 10-K · filed 2013-03-18 | |
| 2009-12-31 | $28.00K 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |